ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

  1. 原著論文

Proton Beam Therapy for Hepatocellular Carcinoma: The University of Tsukuba Experience

https://repo.qst.go.jp/records/45813
https://repo.qst.go.jp/records/45813
099c542a-33cc-4e7c-81cd-9339d2eb139f
Item type 学術雑誌論文 / Journal Article(1)
公開日 2010-06-16
タイトル
タイトル Proton Beam Therapy for Hepatocellular Carcinoma: The University of Tsukuba Experience
言語
言語 eng
資源タイプ
資源タイプ識別子 http://purl.org/coar/resource_type/c_6501
資源タイプ journal article
アクセス権
アクセス権 metadata only access
アクセス権URI http://purl.org/coar/access_right/c_14cb
著者 Nakayama, Hidetsugu

× Nakayama, Hidetsugu

WEKO 455528

Nakayama, Hidetsugu

Search repository
Sugahara, Shinji

× Sugahara, Shinji

WEKO 455529

Sugahara, Shinji

Search repository
Sakurai, Hideyuki

× Sakurai, Hideyuki

WEKO 455530

Sakurai, Hideyuki

Search repository
Tsuboi, Koji

× Tsuboi, Koji

WEKO 455531

Tsuboi, Koji

Search repository
Tokuue, Kouichi

× Tokuue, Kouichi

WEKO 455532

Tokuue, Kouichi

Search repository
et.al

× et.al

WEKO 455533

et.al

Search repository
中山 秀次

× 中山 秀次

WEKO 455534

en 中山 秀次

Search repository
菅原 信二

× 菅原 信二

WEKO 455535

en 菅原 信二

Search repository
坪井 康次

× 坪井 康次

WEKO 455536

en 坪井 康次

Search repository
抄録
内容記述タイプ Abstract
内容記述 BACKGROUND:: The authors have published a series of studies evaluating the safety and efficacy of proton beam therapy for the treatment of hepatocellular carcinoma in a variety of clinical settings. In the current study, they retrospectively reviewed their entire experience treating hepatocellular carcinoma patients with proton beam therapy at their hospital-based facility at the University of Tsukuba. METHODS:: From November 2001 to December 2007, 333 patients with hepatocellular carcinoma were treated with proton beam therapy at the University of Tsukuba. A total of 318 patients were included in this study. Total dose delivered and fractionation scheme were determined by protocols that varied based on location of tumor. Survival rates and prognostic factors were assessed. RESULTS:: Overall actuarial survival rates at 1-year, 3-years, and 5-years were 89.5% (95% confidence interval [95% CI], 85.7-93.1%), 64.7% (95% CI, 56.6-72.9%), and 44.6% (95% CI, 29.7-59.5%), respectively. Child-Pugh liver function (hazards ratio [HR], 2.84; P < .01), T stage (HR, 1.94; P < .05), performance status (HR, 2.12; P < .01), and planning target volume (HR, 2.12; P < .05) significantly impacted survival. The 3-year and 5-year survival rates were 69.1% (95% CI, 59.9-78.3%) and 55.9% (95% CI, 41.5-70.3%), respectively, for patients with Child-Pugh A disease and 51.9% (95% CI, 32.3-71.5%) and 44.5% (95% CI, 23.1-65.8%), respectively, for patients with Child-Pugh B disease. The actuarial survival rates of patients with Child-Pugh class A were statistically different between groups of planned target volume </=125 mL and >125 mL (P < .05). CONCLUSIONS:: The authors have shown proton beam therapy to be both safe and effective for the treatment of patients with hepatocellular carcinoma. They strongly recommend the consideration of proton beam therapy in patients for whom other treatment options are risky or contraindicated.
書誌情報 Cancer

巻 115, 号 23, p. 5499-5506, 発行日 2009-12
ISSN
収録物識別子タイプ ISSN
収録物識別子 0008-543X
戻る
0
views
See details
Views

Versions

Ver.1 2023-05-15 23:59:17.860284
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR 2.0
  • OAI-PMH JPCOAR 1.0
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3